RHOEN-KLINIKUM AG (RHK.DE) Fundamental Analysis & Valuation

FRA:RHK • DE0007042301

Current stock price

12.3 EUR
-0.1 (-0.81%)
Last:

This RHK.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. RHK.DE Profitability Analysis

1.1 Basic Checks

  • In the past year RHK was profitable.
  • RHK had a positive operating cash flow in the past year.
  • Each year in the past 5 years RHK has been profitable.
  • Each year in the past 5 years RHK had a positive operating cash flow.
RHK.DE Yearly Net Income VS EBIT VS OCF VS FCFRHK.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

1.2 Ratios

  • The Return On Assets of RHK (1.89%) is worse than 60.00% of its industry peers.
  • The Return On Equity of RHK (2.61%) is worse than 63.33% of its industry peers.
  • RHK's Return On Invested Capital of 2.24% is on the low side compared to the rest of the industry. RHK is outperformed by 76.67% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for RHK is below the industry average of 6.69%.
Industry RankSector Rank
ROA 1.89%
ROE 2.61%
ROIC 2.24%
ROA(3y)2.14%
ROA(5y)1.92%
ROE(3y)3.02%
ROE(5y)2.69%
ROIC(3y)2.41%
ROIC(5y)2.18%
RHK.DE Yearly ROA, ROE, ROICRHK.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6

1.3 Margins

  • With a Profit Margin value of 2.02%, RHK perfoms like the industry average, outperforming 46.67% of the companies in the same industry.
  • In the last couple of years the Profit Margin of RHK has grown nicely.
  • RHK has a Operating Margin of 2.40%. This is in the lower half of the industry: RHK underperforms 76.67% of its industry peers.
  • In the last couple of years the Operating Margin of RHK has grown nicely.
  • RHK's Gross Margin of 66.87% is fine compared to the rest of the industry. RHK outperforms 66.67% of its industry peers.
  • RHK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.4%
PM (TTM) 2.02%
GM 66.87%
OM growth 3Y1.67%
OM growth 5Y10.96%
PM growth 3Y5.16%
PM growth 5Y80.11%
GM growth 3Y-1.1%
GM growth 5Y-0.61%
RHK.DE Yearly Profit, Operating, Gross MarginsRHK.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RHK.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RHK is destroying value.
  • Compared to 1 year ago, RHK has about the same amount of shares outstanding.
  • Compared to 5 years ago, RHK has about the same amount of shares outstanding.
  • Compared to 1 year ago, RHK has an improved debt to assets ratio.
RHK.DE Yearly Shares OutstandingRHK.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
RHK.DE Yearly Total Debt VS Total AssetsRHK.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 3.26 indicates that RHK is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.26, RHK belongs to the top of the industry, outperforming 86.67% of the companies in the same industry.
  • RHK has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of RHK (0.09) is better than 96.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 3.26
ROIC/WACC0.34
WACC6.65%
RHK.DE Yearly LT Debt VS Equity VS FCFRHK.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 2.60 indicates that RHK has no problem at all paying its short term obligations.
  • The Current ratio of RHK (2.60) is better than 96.67% of its industry peers.
  • A Quick Ratio of 2.49 indicates that RHK has no problem at all paying its short term obligations.
  • RHK has a better Quick ratio (2.49) than 96.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.49
RHK.DE Yearly Current Assets VS Current LiabilitesRHK.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RHK.DE Growth Analysis

3.1 Past

  • RHK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.07%.
  • RHK shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 88.40% yearly.
  • The Revenue has been growing slightly by 6.84% in the past year.
  • The Revenue has been growing slightly by 4.62% on average over the past years.
EPS 1Y (TTM)-21.07%
EPS 3Y11.09%
EPS 5Y88.4%
EPS Q2Q%-25.1%
Revenue 1Y (TTM)6.84%
Revenue growth 3Y5.64%
Revenue growth 5Y4.62%
Sales Q2Q%4.24%

3.2 Future

  • Based on estimates for the next years, RHK will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.44% on average per year.
  • Based on estimates for the next years, RHK will show a small growth in Revenue. The Revenue will grow by 5.72% on average per year.
EPS Next Y17.01%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
EPS Next 5Y13.44%
Revenue Next Year3.99%
Revenue Next 2Y6.38%
Revenue Next 3Y5.92%
Revenue Next 5Y5.72%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RHK.DE Yearly Revenue VS EstimatesRHK.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B 2B
RHK.DE Yearly EPS VS EstimatesRHK.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

3

4. RHK.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 24.12, the valuation of RHK can be described as rather expensive.
  • 70.00% of the companies in the same industry are cheaper than RHK, based on the Price/Earnings ratio.
  • RHK's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.53.
  • With a Price/Forward Earnings ratio of 16.09, RHK is valued correctly.
  • RHK's Price/Forward Earnings ratio is in line with the industry average.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 37.95, RHK is valued rather cheaply.
Industry RankSector Rank
PE 24.12
Fwd PE 16.09
RHK.DE Price Earnings VS Forward Price EarningsRHK.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • RHK's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. RHK is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.36
RHK.DE Per share dataRHK.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20 25

4.3 Compensation for Growth

  • RHK's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as RHK's earnings are expected to grow with 13.68% in the coming years.
PEG (NY)1.42
PEG (5Y)0.27
EPS Next 2Y14.65%
EPS Next 3Y13.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. RHK.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 1.61%, RHK has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 1.83, RHK has a dividend in line with its industry peers.
  • RHK's Dividend Yield is comparable with the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.61%

5.2 History

  • The dividend of RHK decreases each year by -19.15%.
Dividend Growth(5Y)-19.15%
Div Incr Years1
Div Non Decr Years1
RHK.DE Yearly Dividends per shareRHK.DE Yearly Dividends per shareYearly Dividends per share 2019 2023 2025 2026 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

  • RHK pays out 19.44% of its income as dividend. This is a sustainable payout ratio.
DP19.44%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
RHK.DE Yearly Income VS Free CF VS DividendRHK.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M
RHK.DE Dividend Payout.RHK.DE Dividend Payout, showing the Payout Ratio.RHK.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RHK.DE Fundamentals: All Metrics, Ratios and Statistics

RHOEN-KLINIKUM AG

FRA:RHK (4/16/2026, 7:00:00 PM)

12.3

-0.1 (-0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-26
Earnings (Next)05-07
Inst Owners0.53%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap823.61M
Revenue(TTM)1.70B
Net Income(TTM)34.47M
Analysts74.29
Price Target14.54 (18.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.61%
Yearly Dividend0.1
Dividend Growth(5Y)-19.15%
DP19.44%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.59%
PT rev (3m)0.59%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 24.12
Fwd PE 16.09
P/S 0.48
P/FCF N/A
P/OCF 14.4
P/B 0.62
P/tB 0.71
EV/EBITDA 0.36
EPS(TTM)0.51
EY4.15%
EPS(NY)0.76
Fwd EY6.21%
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)0.85
OCFY6.95%
SpS25.46
BVpS19.72
TBVpS17.21
PEG (NY)1.42
PEG (5Y)0.27
Graham Number15.0438 (22.31%)
Profitability
Industry RankSector Rank
ROA 1.89%
ROE 2.61%
ROCE 2.77%
ROIC 2.24%
ROICexc 3.53%
ROICexgc 4.31%
OM 2.4%
PM (TTM) 2.02%
GM 66.87%
FCFM N/A
ROA(3y)2.14%
ROA(5y)1.92%
ROE(3y)3.02%
ROE(5y)2.69%
ROIC(3y)2.41%
ROIC(5y)2.18%
ROICexc(3y)3.18%
ROICexc(5y)2.84%
ROICexgc(3y)3.77%
ROICexgc(5y)3.38%
ROCE(3y)2.99%
ROCE(5y)2.71%
ROICexgc growth 3Y5.1%
ROICexgc growth 5Y14.06%
ROICexc growth 3Y5.79%
ROICexc growth 5Y14.64%
OM growth 3Y1.67%
OM growth 5Y10.96%
PM growth 3Y5.16%
PM growth 5Y80.11%
GM growth 3Y-1.1%
GM growth 5Y-0.61%
F-Score6
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA 1.12
Cap/Depr 152.7%
Cap/Sales 5.81%
Interest Coverage 13.22
Cash Conversion 54.02%
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.49
Altman-Z 3.26
F-Score6
WACC6.65%
ROIC/WACC0.34
Cap/Depr(3y)120.3%
Cap/Depr(5y)111.07%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.07%
EPS 3Y11.09%
EPS 5Y88.4%
EPS Q2Q%-25.1%
EPS Next Y17.01%
EPS Next 2Y14.65%
EPS Next 3Y13.68%
EPS Next 5Y13.44%
Revenue 1Y (TTM)6.84%
Revenue growth 3Y5.64%
Revenue growth 5Y4.62%
Sales Q2Q%4.24%
Revenue Next Year3.99%
Revenue Next 2Y6.38%
Revenue Next 3Y5.92%
Revenue Next 5Y5.72%
EBIT growth 1Y-15.46%
EBIT growth 3Y7.4%
EBIT growth 5Y16.08%
EBIT Next Year147.39%
EBIT Next 3Y44.65%
EBIT Next 5Y34.3%
FCF growth 1Y-173.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-55.17%
OCF growth 3Y-1.74%
OCF growth 5Y-12.78%

RHOEN-KLINIKUM AG / RHK.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?

ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.


What is the valuation status of RHOEN-KLINIKUM AG (RHK.DE) stock?

ChartMill assigns a valuation rating of 3 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.


How profitable is RHOEN-KLINIKUM AG (RHK.DE) stock?

RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.


How financially healthy is RHOEN-KLINIKUM AG?

The financial health rating of RHOEN-KLINIKUM AG (RHK.DE) is 7 / 10.


What is the earnings growth outlook for RHOEN-KLINIKUM AG?

The Earnings per Share (EPS) of RHOEN-KLINIKUM AG (RHK.DE) is expected to grow by 17.01% in the next year.